Introduction
Psoriasis and pemphigus are two chronic inflammatory immune mediated
cutaneous disorders. Rituximab (MabThera, Rituxan) is a chimeric
murine/human anti-CD20 monoclonal antibody known as a potential drug for
treatment of pemphigus vulgaris. It is administrated via intravenous
infusion (1). Here we present a case of a
48-years-old patient affected with pemphigus vulgaris and developed
psoriatic plaques on her scalp, trunk and arms four months after the
second course of rituximab.